In a deal that is likely to alter the biologics landscape in India by catapulting the growth ambitions of Biocon, Ltd. subsidiary Syngene International Ltd. , Syngene and Strides Pharma Science Limited associate company Stelis Biopharma Ltd have entered into a binding term sheet for a slump sale.
Will The $86m Stelis-Syngene Deal Change India’s Biologics Landscape?
Acquired Plant Seen Operational In 2024
Biocon subsidiary Syngene and Strides associate Stelis have entered a deal with the potential to change India’s vaccines and biologics landscape, as the former's growth plans are catapulted. Meanwhile, the Strides group gets to cut debt by selling a unit that made the ill-fated Sputnik Light COVID-19 vaccine and after Akston Biosciences terminated another COVID-19 vaccine alliance
More from Business
More from Scrip
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.